Summary
Signal counts
Assets tracked: 4
Watchlist assets: 1
Registry stop assets: 0
Sponsor overview
University of Michigan Rogel Cancer Center
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT06356155 | https://clinicaltrials.gov/study/NCT07139977 | https://clinicaltrials.gov/study/NCT04995419 | https://clinicaltrials.gov/study/NCT06784336 | https://clinicaltrials.gov/study/NCT02037230 | https://clinicaltrials.gov/study/NCT02158975
Assets
Linked programs
- Enfortumab vedotin: Low Signal (1/5)
- Iron chelation: Low Signal (0/5)
- MK-1775: Low Signal (0/5)
- MLN9708: Watchlist Signal (2/5)